Fintel reports that on January 30, 2025, Stephens & Co. downgraded their outlook for Paragon 28 (NYSE:FNA) from Overweight to Equal-Weight. Analyst Price Forecast Suggests 12.29% Upside As of January ...

Paragon 28, Inc. (NYSE:FNA – Get Free Report) has earned a consensus rating of “Hold” from the six ratings firms that are presently covering the company, Ratings reports. Four research analysts have ...

JPMorgan Chase & Co. raised its position in Paragon 28 by 2,141.7% during the third quarter. JPMorgan Chase & Co. now owns 784,878 shares of the company’s stock valued at $5,243,000 after ...

Piper Sandler & Co. is serving as exclusive financial advisor to Paragon 28 and Cravath, Swaine & Moore LLP is serving as legal advisor. About Zimmer Biomet Zimmer Biomet is a global medical ...

Piper Sandler & Co is to provide exclusive financial advisory services for Paragon 28 while Cravath, Swaine & Moore will act as its legal advisers. Last month, Zimmer Biomet received 510(k ...

Piper Sandler & Co. is serving as exclusive financial advisor to Paragon 28 and Cravath, Swaine & Moore LLP is serving as legal advisor. Zimmer Biomet is a global medical technology leader with ...

Piper Sandler & Co. is serving as exclusive financial advisor to Paragon 28 and Cravath, Swaine & Moore LLP is serving as legal advisor. About Zimmer Biomet Zimmer Biomet is a global medical ...

Zimmer Biomet to buy medical device company, Paragon 28 for $1.2 billion: Warsaw, Indiana Thursday, January 30, 2025, 14:00 Hrs [IST] Zimmer Biomet Holdings, Inc., a global medica ...

Piper Sandler & Co. is serving as exclusive financial advisor to Paragon 28 and Cravath, Swaine & Moore LLP is serving as legal advisor. About Zimmer Biomet Zimmer Biomet is a global medical ...